18 March 2020 in Applied and Environmental Microbiology
UPOs catalyze regio- and stereoselective oxygenations of both aromatic and aliphatic compounds. Similar reactions were previously described for cytochrome P450 monooxygenases, but UPOs have the noteworthy biotechnological advantage of being stable enzymes requiring only H 2 O 2 to be activated. Both characteristics are related to the extracellular nature of UPOs as secreted proteins. In the present study, the limited repertoire of UPO enzymes available for organic synthesis and other applications is expanded with the description of two new ascomycete UPOs obtained by Escherichia coli expression of the corresponding genes as soluble and active enzymes. Moreover, directed mutagenesis in E. coli , together with enzyme molecular modeling, provided relevant structure-function information on aromatic substrate oxidation by these two new biocatalysts.
10 January 2020 in Catalysis Science & Technology
Enzyme-driven oxygenation reactions are in the spotlight for organic synthesis. In this regard, a heme-thiolate unspecific peroxygenase (UPO) from the fungus Chaetomium globosum has recently proven to be a suitable catalyst for selective epoxidation of unsaturated fatty acids in the context of the bio-based industry, but this enzyme could not be expressed in Escherichia coli for directed mutagenesis studies. Here, a previously unknown UPO from the related Collariella virescens (synonym: Chaetomium virescens) was obtained by E. coli expression of a putative upo gene. The activity of the purified enzyme on unsaturated fatty acids with different lengths and unsaturation degrees was tested. The ability of C. virescens UPO to epoxidize these compounds increases in the order myristoleic acid (C14:1) < palmitoleic acid (C16:1) < oleic acid (C18:1) differing from that observed for the C. globosum UPO, which also forms less hydroxylated derivatives. Given the possibility to produce the C. virescens UPO in E. coli as a recombinant enzyme and its oxyfunctionalization ability, some mutated variants were obtained mimicking the active-site of C. globosum UPO and evaluated on 18-carbon unsaturated fatty acids. Results revealed that widening the heme-access channel of C. virescens UPO by substituting a phenylalanine residue (in a F88L variant) maintains the enzyme epoxidation activity, and reduces undesired hydroxylation side-reactions (from 34% to only 7% of linoleic acid products) approaching the oxyfunctionalization pattern obtained with C. globosum UPO, although maintaining the absence of diepoxides. Conversely, its partial occlusion by introducing a second phenylalanine residue (in a T158F variant) resulted in partial selective epoxidation of linoleic acid (C18:2), while the oleic acid epoxidation was prevented. The above results show how E. coli expression can speed up the availability of new UPOs, and the design of ad hoc variants of these self-sufficient monooxygenases.
2 December 2022 in bioRxiv
M. brumae is a rapid-growing, non-pathogenic Mycobacterium species, originally isolated from environmental and human samples in Barcelona, Spain. M. brumae is not pathogenic and its in vitro phenotype and immunogenic properties have been well characterized. However, the knowledge of its underlying genetic composition is still incomplete. In this study, we first describe the 4 Mb genome of the M. brumae type strain ATCC 51384T assembling PacBio reads, and second, we assess the low intraspecies variability by comparing the type strain with Illumina reads from three additional strains. M. brumae genome is composed of a circular chromosome with a high GC content of 69.2 % and containing 3,791 CDSs, 97 pseudogenes, one prophage and no CRISPR loci. M. brumae has shown no pathogenic potential in in vivo experiments, and our genomic analysis confirms its phylogenetic position with other non-pathogenic and rapid growing mycobacteria. Accordingly, we determined the absence of virulence related genes, such as ESX-1 locus and most PE/PPE genes, among others. Although immunogenic potential of M. brumae was proved to be as high as Mycobacterium bovis BCG, the only mycobacteria licensed to treat cancer, the genomic content of M. tuberculosis T cell and B cell antigens in M. brumae is considerably lower than those of M. bovis BCG. Overall, this work provides relevant genomic data on one of the species of the mycobacterial genus with high therapeutic potential.